Is hydroxychloroquine beneficial for COVID-19 patients?

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world1–3, the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 20204. The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir5, to control the disease and halt the pandemic.

Serological Determinants of COVID-19

“…In Table 3 the summary statistics is presented. As it can been seen, the speci city of both COVID- 19…”

“…The S2 segment anchors the S protein to the viral membrane, contains the fusion peptide which mediates the fusion of the viral membrane with the plasma membrane of the target cell. The proteases responsible for the S protein activation represents promising drug targets for the treatment of the disease, following failure of rst attempts, such as hydroxychloroquine 19 .…”

Medical management of COVID-19: treatment options under consideration

“…Given this report, on 30 March 2020, the US FDA gave Emergency Use Authorization (EUA) to HCQ/CQ for treatment of COVID-19, in the absence of any other approved therapy. 4 In a retrospective multicenter cohort study in 25 different hospitals on 1438 patients with distinct medications and pre-existing conditions, there were no significant differences in mortality for patients receiving HCQ + azithromycin, HCQ alone, or azithromycin alone. On 24 April 2020, FDA cautioned against the use of CQ/HCQ outside the hospital settings or a clinical trial.…”

Consensus Scientific Statement on Advisory Working Guidelines and Recommendations for the Female Population in COVID-19 Era by WINCARS

“…No need to discontinue this drug during pregnancy. 51 If Systemic lupus erythematosus (SLE) women on this drug become pregnant; it has not shown any adverse effects on the fetus even though the cord blood sample has the same concentration of the drug of the mother serum concentration.…”